MannKind Corp. Stock
MannKind Corp. Stock
The price for the MannKind Corp. stock decreased slightly today. Compared to yesterday there is a change of -€0.029 (-0.620%).
With 23 Buy predictions and not a single Sell prediction MannKind Corp. is an absolute favorite of our community.
With a target price of 8 € there is a hugely positive potential of 71.27% for MannKind Corp. compared to the current price of 4.67 €.
So far the community has only identified positive things for MannKind Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of MannKind Corp. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
B****
Cons
?
S********** s********
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of MannKind Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| MannKind Corp. | -0.620% | 1.090% | 2.293% | -13.102% | -4.116% | -7.889% | -3.863% |
| Biocryst Pharmaceuticals | -0.120% | 10.239% | 12.387% | -18.207% | -1.464% | -25.162% | -33.512% |
| Heron Therapeutics Inc. | -10.110% | -7.850% | -25.626% | -45.666% | -17.280% | -57.269% | -93.736% |
| Madrigal Pharmaceuticals inc. | -1.100% | -9.044% | -8.016% | 21.382% | -24.955% | 42.786% | 270.213% |
Comments
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Show more
Ratings data for MNKD provided by MarketBeat
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Show more
Ratings data for MNKD provided by MarketBeat
MannKind (NASDAQ:MNKD) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Show more
Ratings data for MNKD provided by MarketBeat
News
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares?
On Dec. 17, 2025, Michael Castagna, Chief Executive Officer of MannKind Corporation (NASDAQ:MNKD), executed an exercise and immediate sale of 65,804 common shares for a transaction value of
